Combatting the 21st century global public health problems through revolutionary i-αVLP Technology.

SEE OUR TECHNOLOGY
103, 2017

VLP Therapeutics Appoints Danai Brooks, Managing Partner of Glen Echo Capital, to Advisory Board

Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that Danai Brooks, Managing Partner

501, 2017

VLP Therapeutics was featured in a TV program (January 5, 2017)

VLP Therapeutics was featured in a TV program in Japan. (January 5, 2017) YouTube https://www.youtube.com/watch?v=X0L8k7Wf7P8

1111, 2016

VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)

VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.